scholarly journals Manual on the proper use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials

2019 ◽  
Vol 33 (11) ◽  
pp. 787-805 ◽  
Author(s):  
Makoto Hosono ◽  
Hideharu Ikebuchi ◽  
Seigo Kinuya ◽  
Sachiko Yanagida ◽  
Yoshihide Nakamura ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Nuclear Medicine ◽  
Radiation Protection ◽  
Radionuclide Therapy ◽  
Japanese Society ◽  
Radiation Safety ◽  
Japanese Version ◽  
Ministry Of Health ◽  
Safety Issues ◽  
Yttrium 90

Abstract We present the guideline for use of yttrium-90-labeled anti-P-cadherin antibody injection for radionuclide therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine. Treatment using yttrium-90-labeled anti-P-cadherin antibody injection in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection shown here are considered internationally useful as well. Only the original Japanese version is the formal document.

scholarly journals Manual on the proper use of sodium astatide ([211At]NaAt) injections in clinical trials for targeted alpha therapy (1st edition)

2021 ◽  
Author(s):  
Tadashi Watabe ◽  
Makoto Hosono ◽  
Seigo Kinuya ◽  
Takahiro Yamada ◽  
Sachiko Yanagida ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Japanese Society ◽  
Radiation Safety ◽  
Safety Management ◽  
Evaluation Methodology ◽  
Targeted Alpha Therapy ◽  
Safety Issues ◽  
Safety Standards ◽  
And Training ◽  
Alpha Therapy

AbstractWe present the guideline for use of [211At] sodium astatide (NaAt) for targeted alpha therapy in clinical trials on the basis of radiation safety issues in Japan. This guideline was prepared by a study supported by the Ministry of Health, Labour, and Welfare, and approved by the Japanese Society of Nuclear Medicine on 8th Feb, 2021. The study showed that patients receiving [211At]NaAt do not need to be admitted to a radiotherapy room and outpatient treatment is possible. The radiation exposure from the patient is within the safety standards of the ICRP and IAEA recommendations for the general public and caregivers. Precautions for patients and their families, safety management associated with the use of [211At]NaAt, education and training, and disposal of medical radioactive contaminants are also included in this guideline. Treatment using [211At]NaAt in Japan should be carried out according to this guideline. Although this guideline is applied in Japan, the issues for radiation protection and evaluation methodology shown here are considered internationally useful as well.

scholarly journals Clinical trials in molecular radiotherapy—Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018

2019 ◽  
Vol 92 (1100) ◽  
pp. 20190117 ◽  
Author(s):  
Nadia Falzone ◽  
Rebecca Gregory ◽  
Matthew Aldridge ◽  
Samantha YA Terry ◽  
Glenn Flux
Keyword(s):  
Clinical Trials ◽  
Nuclear Medicine ◽  
Radionuclide Therapy ◽  
Targeted Radionuclide Therapy ◽  
Molecular Radiotherapy ◽  
Challenges And Opportunities ◽  
The Uk

It has been almost a decade since the commentary Molecular radiotherapy — the radionuclide raffle? by Gaze and Flux (2010). The overarching feeling then was that no individual or organisation has taken up the challenge, nationally or internationally, of championing molecular targeted radionuclide therapy in all its aspects. Here, we report on the recent NCRI–CTRad (Clinical Trials in Molecular Radiotherapy–Tribulations and Triumphs) meeting, held in London on the 8 June 2018. The meeting was organized by the NCRI–CTRad to review the challenges and opportunities for clinical trials in molecular radiotherapy, particularly focussing on investigator-led trials that incorporate imaging and dosimetry, and to discuss how the community can move forward. This meeting was organised in conjunction with the British Nuclear Medicine Society and reflects the progress of Nuclear Medicine in the UK.

scholarly journals Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator, for Easy Use in Radionuclide Therapy

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Maria Argyrou ◽  
Alexia Valassi ◽  
Maria Andreou ◽  
Maria Lyra
Keyword(s):  
Nuclear Medicine ◽  
Radiation Dose ◽  
Radionuclide Therapy ◽  
Radiation Safety ◽  
Low Cost ◽  
High Energy ◽  
Therapeutic Applications ◽  
Total Radiation Dose ◽  
Absorbed Radiation Dose ◽  
Effective Penetration

Rhenium-188 (Re-188) is a high energy -emitting radioisotope obtained from the tungsten-188/rhenium-188 (W-188/Re-188) generator, which has shown utility for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology. Re-188 decay is accompanied by a 155 keV predominant energy -emission, which could be detected by -cameras, for imaging, biodistribution, or absorbed radiation dose studies. Its attractive physical properties and its potential low cost associated with a long-lived parent make it an interesting option for clinical use. The setup and daily use of W-188/Re-188 generator in hospital nuclear medicine departments are discussed in detail. The clinical efficacy, for several therapeutic applications, of a variety of Re-188-labeled agents is demonstrated. The high energy of the -emission of Re-188 is particularly well suited for effective penetration in solid tumours. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy. Furthermore, radiation safety and shielding requirements are an important subject of matter. In the case of bone metastases treatment, therapeutic ratios are presented in order to describe the efficacy of Re-188 usage.

scholarly journals Radiation Protection in Nuclear Medicine in Eastern Province, KSA

2019 ◽  
Vol 4 (2) ◽  
Keyword(s):  
Nuclear Medicine ◽  
Patient Safety ◽  
Radiation Protection ◽  
General Public ◽  
Radionuclide Therapy ◽  
Eastern Province ◽  
Staff Members ◽  
Intention To Treat ◽  
Diagnostic Nuclear Medicine ◽  
Therapeutic Nuclear Medicine

In nuclear medicine, radiopharmaceuticals are administered to the patient either for the production of diagnostic images or with the intention to treat using the emitted radiation from the radiopharmaceutical. The increased use of PET-imaging causes a need for new planning of radiation protection. In radionuclide therapy, the activities are higher and the radionuclides used are often different from those used in diagnostic nuclear medicine and constitute a greater radiation protection problem. In both diagnostic and therapeutic nuclear medicine, the patient becomes a source of radiation not only for him/herself but also for staff, caregivers and the general public. All categories of staff members involved in nuclear medicine must have good knowledge of radiation protection. This is vital for patient safety as well as for the staff's own security, for caregivers and the general public.

scholarly journals Radiation Safety Guide: General Definitions and Radiation Protection Rules in Nuclear Medicine Applications

2020 ◽  
Vol 6 (2) ◽  
pp. 71-89
Author(s):  
Yasemin Parlak ◽  
Bağnu Uysal ◽  
F. Suna Kıraç ◽  
Bilal Kovan ◽  
Mustafa Demir ◽  
...  
Keyword(s):  
Nuclear Medicine ◽  
Radiation Protection ◽  
Radiation Safety

scholarly journals Nuclear Medicine Imaging in the Pediatric Patient

2006 ◽  
Vol 11 (4) ◽  
pp. 200-211
Author(s):  
Vivian Loveless
Keyword(s):  
Nuclear Medicine ◽  
Pediatric Patients ◽  
Radiation Safety ◽  
Endocrine System ◽  
Nuclear Medicine Imaging ◽  
Safety Issues ◽  
Disease States ◽  
Pulmonary System ◽  
Pediatric Nuclear Medicine ◽  
The Central Nervous System

Pediatric nuclear medicine provides a wealth of information on a variety of disease states; however, precautions on dosing have to be taken into consideration. Also, expertise in conducting procedures and interpreting the results in pediatric patients is necessary. Emphasis is placed on diagnostic studies involving the central nervous system, musculoskeletal system, genitourinary system, gastrointestinal system, endocrine system, pulmonary system, and cardiovascular system along with a brief explanation of the mechanism of localization of the radiopharmaceuticals involved. Radiation safety issues are addressed when the expectant mother or nursing mother is administered radiopharmaceuticals.

scholarly journals Radiation Safety of Current European Practices of Therapeutic Nuclear Medicine: Survey Results from 20 HERCA Countries

2020 ◽  
Author(s):  
Ritva Bly
Keyword(s):  
Nuclear Medicine ◽  
Waste Management ◽  
Treatment Planning ◽  
Radiation Protection ◽  
Radiation Safety ◽  
Individual Treatment ◽  
Radiological Protection ◽  
Member States ◽  
Almost All ◽  
Therapeutic Nuclear Medicine

Abstract Purpose: New radiotherapies in nuclear medicine have been introduced in Europe during recent years. Moreover, radiation safety of therapeutic nuclear medicine should be in line with the latest European Council Directive on Basic Safety Standards (BSSD) (2013/59/Euratom). The purpose of this study was to acquire up-to-date information on nuclear medicine treatments in Europe and on the implementation of the requirements of the BSSD in HERCA (Heads of the European Radiological protection Competent Authorities) member states. Methods: An electronic questionnaire was distributed to competent authorities of 32 HERCA member states. The questionnaire addressed 33 explicitly considered treatments including 13 different radionuclides, and for each treatment, a similar set of questions was included. Questions covered the use of treatments, hospitalization of patients and waste management related to therapeutic nuclear medicine involving other radionuclides than 131 I, justification of treatments, individual treatment planning, involvement of a medical physics expert (MPE) and radiation protection instructions related to release of the patient.Results: Responses were obtained from 20 HERCA countries. All countries used 131 I-NaI for benign thyroid diseases and thyroid ablation of adults. 223 RaCl2 (Xofigo®) for bone metastases, 177 Lusomatostatin analogues for neuroendocrine tumors and 177 Lu-PSMA for castration resistant prostate cancer (PC) and PC-metastases were used in 90%, 65% and 55% of countries respectively. Only a few countries had treatment specific criteria for hospitalization and waste management for new treatments. Requirements for justification of new therapies were in place in almost all countries. Individual treatment planning was required for all therapies in 55% and for some therapies in 28% of the responding countries. Implementation of the requirement for MPEs to be closely involved in nuclear medicine practices varied to a great extend among countries. Almost all countries answered that some radiation protection instructions existed for patients released after other than 131 I treatment, however in a very few countries had specific guidelines been developed.Conclusions: There is a wide variation in therapeutic use of nuclear medicine across Europe, but there is an increasing tendency towards these types of treatments. Furthermore, the implementation of the BSSD on the involvement of MPEs and individual treatment planning including dosimetry differs from country to country. Requirements on justification are in place.

Radiation Safety in Nuclear Medicine: Report I. Topical Problems

2021 ◽  
Vol 66 (1) ◽  
pp. 29-36
Author(s):  
Boris Narkevich
Keyword(s):  
Nuclear Medicine ◽  
Radionuclide Therapy ◽  
Radiation Safety ◽  
Current State ◽  
Radionuclide Diagnostics

The current state and prospects of ensuring radiation safety in the nuclear medicine divisions of Russia are analyzed. The literature data and the main results of our own research to ensure the radiation safety of patients, staff, caregivers and the environment in the departments of radionuclide diagnostics and radionuclide therapy are presented. The most important and requiring solutions to ensure radiation safety in nuclear medicine are considered.

Radiation exposure of the staff at the therapeutic and diagnostic nuclear medicine department

2008 ◽  
Vol 47 (04) ◽  
pp. 175-177 ◽  
Author(s):  
J. Dolezal
Keyword(s):  
Nuclear Medicine ◽  
Radiation Exposure ◽  
Effective Dose ◽  
Radiation Protection ◽  
Annual Effective Dose ◽  
Protection Measures ◽  
Professional Groups ◽  
Personal Dosimetry ◽  
The Mean ◽  
Administered Activity

SummaryAim: To assess a radiation exposure and the quality of radiation protection concerning a nuclear medicine staff at our department as a six-year retrospective study. Therapeutic radionuclides such as 131I, 153Sm, 186Re, 32P, 90Y and diagnostic ones as a 99mTc, 201Tl, 67Ga, 111In were used. Material, method: The effective dose was evaluated in the period of 2001–2006 for nuclear medicine physicians (n = 5), technologists (n = 9) and radiopharmacists (n = 2). A personnel film dosimeter and thermoluminescent ring dosimeter for measuring (1-month periods) the personal dose equivalent Hp(10) and Hp(0,07) were used by nuclear medicine workers. The wearing of dosimeters was obligatory within the framework of a nationwide service for personal dosimetry. The total administered activity of all radionuclides during these six years at our department was 17,779 GBq (99mTc 14 708 GBq, 131I 2490 GBq, others 581 GBq). The administered activity of 99mTc was similar, but the administered activity of 131I in 2006 increased by 200%, as compared with the year 2001. Results: The mean and one standard deviation (SD) of the personal annual effective dose (mSv) for nuclear medicine physicians was 1.9 ± 0.6, 1.8 ± 0.8, 1.2 ± 0.8, 1.4 ± 0.8, 1.3 ± 0.6, 0.8 ± 0.4 and for nuclear medicine technologists was 1.9 ± 0.8, 1.7 ± 1.4, 1.0 ± 1.0, 1.1 ± 1.2, 0.9 ± 0.4 and 0.7 ± 0.2 in 2001, 2002, 2003, 2004, 2005 and 2006, respectively. The mean (n = 2, estimate of SD makes little sense) of the personal annual effective dose (mSv) for radiopharmacists was 3.2, 1.8, 0.6, 1.3, 0.6 and 0.3. Although the administered activity of 131I increased, the mean personal effective dose per year decreased during the six years. Conclusion: In all three professional groups of nuclear medicine workers a decreasing radiation exposure was found, although the administered activity of 131I increased during this six-year period. Our observations suggest successful radiation protection measures at our department.

Sign in / Sign up

Export Citation Format

Share Document